A large meta-analysis that included data from 56,004 individuals enrolled in GLP-1 RA CVOTs showed no association between the use of GLP-1 analogs and the risk of pancreatic cancer or acute pancreatitis [75]. Here, GLP1R is linked to pancreatic neoplasm.